InVivo in the News

InVivo makes it official: Richard Toselli becomes president and CEO, joins board

Published: February 5, 2018

(FierceBiotech) InVivo Therapeutics, which specializes in spinal cord injuries, named Richard Toselli, M.D., as its president and chief executive. Toselli, who has been acting CEO since December, was also appointed to the company’s board.

The move comes just a week after the company announced a stock purchase deal to sell as much as $15 million worth of stock to Lincoln Park Capital Fund over the next two years.

View Article
InVivo Therapeutics inks $15m share purchase agreement

Published: January 26, 2018

(MassDevice)InVivo Therapeutics (NSDQ:NVIV) said today it inked a stock purchase agreement with Lincoln Park Capital Fund to sell up to $15 million in shares over a two-year period.

The new agreement comes with conditions and limitations, including giving the rights to InVivo to control the timing and amount of sales of stock and that the purchase price is based on prevailing market prices.

View Article
InVivo Therapeutics : Rehab Improving AIS Grade of SCI May Help Lower Lifetime Hospitalization Costs

Published: September 5, 2017

( study published recently in Neurosurgery estimates the lifetime economic costs of spinal cord injury (SCI) associated with hospitalizations in relation to American Spinal Injury Association Impairment Scale (AIS) grade.

View Article
InVivo touts 2 patient recoveries in Inspire trial

Published: June 28, 2017

(MassDevice) InVivo Therapeutics (NSDQ:NVIV) said today that 2 patients in the Inspire trial of its Neuro-Spinal Scaffold have shown significant improvements in motor recovery assessments. The Cambridge, Mass.-based company’s Neuro-Spinal Scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting.

View Article
Two spinal cord injury patients show improvement after receiving InVivo’s Neuro-Spinal Scaffold; shares ahead 13% premarket

Published: June 28, 2017

(Seeking Alpha)InVivo Therapeutics (NASDAQ:NVIV) perks up 13% premarket on modest volume in response to its announcement that two spinal cord injury patients in the INSPIRE study who received its Neuro-Spinal Scaffold have improved from sensory incomplete AIS B status to motor incomplete AIS C, the second and third patients to reach this level.

View Article
InVivo Therapeutics (NVIV) Announces Seventh Patient Conversion In The INSPIRE Study Of The Neuro-Spinal Scaffold

Published: March 28, 2017

( CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement. Two additional patients are early in follow-up and have not yet had their one-month visit. The AIS conversion rate observed in the INSPIRE study to date is considerably higher than published rates observed in a range of SCI natural history databases that are all below 25%.

View Article
Using a Mini-Scaffold to Help Treat Spinal Cord Injury

Published: February 28, 2017

(Bioscience Technology) Patients suffering from complete spinal cord injuries have little to no treatment options that provide meaningful improvement in patient outcomes.
Cambridge, Mass.-based InVivo Therapeutics is trying to change that. Co-founded in 2005 by MIT professor Robert Langer, and surgeon-scientists Joseph Vacanti, M.D., the company has developed a small, bioresorbable and biocompatible device called the Neuro-Spinal Scaffold, to help patients with complete thoracic spinal cord injuries regain some function.

View Article
The Edison of Medicine

Published: February 23, 2017

(Harvard Business Review) One morning last year, James Dahlman came to Bob Langer’s office at MIT’s Koch Institute for Integrative Cancer Research to say good-bye. He was meeting with Langer and Dan Anderson—his doctoral advisers. The 29-year-old was about to take up his first faculty position, in the biomedical engineering department at Georgia Tech, and he wanted their advice.

View Article
InVivo’s Perrin on Developments in Spinal Cord Injury Treatment

Published: February 14, 2017

(Bloomberg Markets AM) GUEST: Mark Perrin, CEO of InVivo Therapeutics (NVIV), on highlights from the BIO CEO conference, and developments in the company’s spinal cord injury treatment.

View Article
Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

Published: November 21, 2016

(STAT News) Jesi Stracham used to captivate biotech investors and inadvertently move markets with social media posts documenting her dogged quest to get out of her wheelchair and back onto her feet.

These days, the energetic 24-year-old North Carolina resident goes online to tell a different story. Many of her Facebook and Instagram posts show her competing in off-road vehicle races, an adaptive water skiing competition, and a pageant for women with disabilities.

View Article

The articles contained in this section of the website are written and published by persons not affiliated with InVivo. The views expressed in these articles are those of the author(s) and do not reflect the views of InVivo. Additionally, the information contained in these articles may not be current. InVivo disclaims any obligation to correct or to update the information contained in these articles.